Evidence map›Paper›PMID 26672768›Full record

ArticleOncotarget2016

Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations.

Susanne Lorenz, Tale Barøy, Jinchang Sun, Torfinn Nome, Daniel Vodák, Jan-Christian Bryne, Anne-Mari Håkelien, Lynnette Fernandez-Cuesta, Birte Möhlendick, Harald Rieder and 11 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 85 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. YBX1-interacting small RNAs andJournal of bone oncology · 2023
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 5 countries.

Susanne LorenzDepartment of Tumor Biology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.
Tale BarøyDepartment of Tumor Biology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.
Jinchang SunGenomics Core Facility, Department of Core Facilities, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.
Torfinn NomeDepartment of Molecular Oncology, Institute for Cancer research, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.
Daniel VodákDepartment of Tumor Biology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.
Jan-Christian BryneDepartment of Tumor Biology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.
Anne-Mari HåkelienDepartment of Tumor Biology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.
Lynnette Fernandez-CuestaDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany.
Birte MöhlendickInstitute for Human Genetics, University Hospital Düsseldorf, Düsseldorf, Germany.
Harald RiederInstitute for Human Genetics, University Hospital Düsseldorf, Düsseldorf, Germany.
Karoly SzuhaiDepartment of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands.
Olga ZaikovaClinic for Cancer, Surgery and Transplantation, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.
Terje C AhlquistDepartment of Molecular Oncology, Institute for Cancer research, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.
Gard O S ThomassenDepartment of Molecular Oncology, Institute for Cancer research, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.
Rolf I SkotheimDepartment of Molecular Oncology, Institute for Cancer research, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.
Ragnhild A LotheDepartment of Molecular Oncology, Institute for Cancer research, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.
Patrick S TarpeyWellcome Trust Sanger Institute, Hinxton, UK.
Peter CampbellWellcome Trust Sanger Institute, Hinxton, UK.
Adrienne FlanaganRoyal National Orthopaedic Hospital, Middlesex, UK.
Ola MyklebostDepartment of Tumor Biology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.
Leonardo A Meza-ZepedaDepartment of Tumor Biology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.
Oslo University Hospital · NOUniversity of Oslo · NOOslo Cancer Cluster · NOWellcome Sanger Institute · GBDüsseldorf University Hospital · DEHeinrich Heine University Düsseldorf · DELeiden University Medical Center · NLUniversity College London · GBUniversity of Cologne · DE

Funding

World Health Organization 001
6 · The paper itself

Abstract

In contrast to many other sarcoma subtypes, the chaotic karyotypes of osteosarcoma have precluded the identification of pathognomonic translocations. We here report hundreds of genomic rearrangements in osteosarcoma cell lines, showing clear characteristics of microhomology-mediated break-induced replication (MMBIR) and end-joining repair (MMEJ) mechanisms. However, at RNA level, the majority of the fused transcripts did not correspond to genomic rearrangements, suggesting the involvement of trans-splicing, which was further supported by typical trans-splicing characteristics. By combining genomic and transcriptomic analysis, certain recurrent rearrangements were identified and further validated in patient biopsies, including a PMP22-ELOVL5 gene fusion, genomic structural variations affecting RB1, MTAP/CDKN2A and MDM2, and, most frequently, rearrangements involving TP53. Most cell lines (7/11) and a large fraction of tumor samples (10/25) showed TP53 rearrangements, in addition to somatic point mutations (6 patient samples, 1 cell line) and MDM2 amplifications (2 patient samples, 2 cell lines). The resulting inactivation of p53 was demonstrated by a deficiency of the radiation-induced DNA damage response. Thus, TP53 rearrangements are the major mechanism of p53 inactivation in osteosarcoma. Together with active MMBIR and MMEJ, this inactivation probably contributes to the exceptional chromosomal instability in these tumors. Although rampant rearrangements appear to be a phenotype of osteosarcomas, we demonstrate that among the huge number of probable passenger rearrangements, specific recurrent, possibly oncogenic, events are present. For the first time the genomic chaos of osteosarcoma is characterized so thoroughly and delivered new insights in mechanisms involved in osteosarcoma development and may contribute to new diagnostic and therapeutic strategies.

Indexed as

DNA RepairGenes, p53Genes, Tumor SuppressorGenomicsHumansOsteosarcomaTranslocation, Geneticbone cancerDNA repairgene fusionosteosarcomastrans-splicing

Identifiers

PMID26672768
PMCPMC4868685
OpenAlexW2213752852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.